Watson Pharmaceuticals clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 30 studies whose lead sponsor is Watson Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 10, 2015.

Studies

Recruiting first, then most recently updated. Showing 30 of 30. All AbbVie studies →

• DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)CompletedNCT00224081Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary HyperhidrosisCompletedNCT02193139Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Study of Silodosin to Facilitate Passage of Urinary StonesCompletedNCT01144949Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in ContraceptionCompletedNCT01140217Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue AdministrationCompletedNCT01161563Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.CompletedNCT00223977Phase 2/3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder SyndromeCompletedNCT00919113Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine LeiomyomaWithdrawnNCT01553123Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal SystemsCompletedNCT01323140Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A Comparison of Patch vs. Pill Estrogen Therapy on Testosterone Levels and Thyroid Tests in Menopausal WomenCompletedNCT00224094Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Effects of Oxybutynin Topical Gel on Gastric EmptyingCompletedNCT00926926Phase 1

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal MenCompletedNCT01104246Phase 1

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Effect of Two Iron Preparations on Protein in the UrineCompletedNCT00354692Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis PatientsCompletedNCT00223964Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) PatientsCompletedNCT00224055Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic AgentsCompletedNCT00224042Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic HyperplasiaCompletedNCT00793819Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer ChemotherapyCompletedNCT00224068Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome.CompletedNCT00740779Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological ConditionCompletedNCT00224016Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive BladderCompletedNCT00224146Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Comparison Between Effects of Two Iron Preparations on Protein in the UrineCompletedNCT00534144Phase 1

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older VolunteersCompletedNCT00752141Phase 1

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With PlaceboCompletedNCT00224107Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A Comparison of a New Drug to Treat Overactive Bladder vs. PlaceboCompletedNCT00350636Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological ConditionCompletedNCT00224029Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 MonthsCompletedNCT00224133Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With PlaceboCompletedNCT00224120Phase 3

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.CompletedNCT00527917Phase 2

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie

• Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis PatientsCompletedNCT00224003Phase 4

  Sponsor listed in the registry: Watson Pharmaceuticals · First submitted before Watson Pharmaceuticals became part of AbbVie